Uploaded November 2022 | Updated September 2026, 1 week ago
inClinico is capable of predicting the probability of success, identifying
weaknesses in clinical trial protocols before implementation, and measuring
PoS with phase transitions using AI-driven software. The platform predicts
the most critical future, the outcome of the most costly and time-consuming
stage in therapeutic commercialization.
inClinico is capable of predicting the probability of success, identifying
weaknesses in clinical trial protocols before implementation, and measuring
PoS with phase transitions using AI-driven software. The platform predicts
the most critical future, the outcome of the most costly and time-consuming
stage in therapeutic commercialization.
![[Nature Communications] Oral ENPP1 Inhibitor as Next Generation STING Modulator for Solid Tumors](https://i.ytimg.com/vi/R9wa1NeqVZg/mqdefault.jpg "[Nature Communications] Oral ENPP1 Inhibitor as Next Generation STING Modulator for Solid Tumors
Cold tumors are cancers with little to no immune cell infiltration. They lack the ability to activate the immune system, leaving patients with few options. Recently, Insilico Medicine announced breakthrough findings in immune oncology therapy targeting ENPP1, published in Nature Communications, a leading peer reviewed journal.")
